3 news items
Praxis Precision Medicines Advances Precision Therapies for CNS Disorders, Anticipates Key Milestones in Seizure and Pediatric Epilepsy Treatment
PRAX
13 May 24
resources and reported positive photo paroxysmal response (PPR) results in PRAX-628, which we believe further de-risks our clinical development program
Why Praxis Precision Medicines Stock Is Trading Higher Tuesday
PRAX
26 Mar 24
) provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with photo paroxysmal response (PPR
Praxis Precision Medicines Reports Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
PRAX
26 Mar 24
- Prev
- 1
- Next